Barcelona 2022

---

Update on pulmonary embolism management

Symposium
Chairs: M. Lichtblau (Zürich, Switzerland), M. Humbert (Le Kremlin-Bicêtre, France), L. Bertoletti (Saint Etienne Cedex, France)
Aims: to discuss guidelines that help identify risk factors for pulmonary embolism (PE) and venous thromboembolism (VTE); to debate definitions and their major impact on management of the disease (extended vs. short-term anticoagulant therapy); to assess the adequacy of these risk factors and whether treatment with direct-acting oral anticoagulants should reconsider any of them; to review the scores and data available to help decide when to continue or suspend anticoagulant treatment; to review the risk of thrombosis associated with COVID-19; to describe anticoagulation regimens used to treat VTE and prophylaxis to prevent recurrence in hospitalised patients; to explain the proper anticoagulation strategies for hospitalised COVID-19 patients and define the proper anticoagulation for outpatients in the active or convalescent phase of infection.

Cancer-associated thrombosis: case fatality rates and scores to balance the risks and benefits of long-term anticoagulant treatment M. Carrier (Ottawa (ON), Canada)
Prevention and treatment of pulmonary embolism related to COVID-19 S. Zuily (Vandoeuvre-lès-Nancy, France)
Relevance of the term “provoked” in the management of PE: PRO F. Couturaud (Brest, France)
Relevance of the term “provoked” in the management of PE: CON R. Otero Candelera (Sevilla, Spain)
Discussion and Q&A